In the first-line setting for postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer, the combination of ribociclib and letrozole demonstrated a statistically significant and clinically meaningful overall survival benefit compared with letrozole alone.
Read More
Atezolizumab Combined With Cabozantinib Shows Efficacy in High-Risk mCRPC
September 19th 2021According to updated data from the phase 1b COSMIC-021 trial, treatment with cabozantinib and atezolizumab continued to demonstrate clinically meaningful activity in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, including those with high-risk clinical features.
Read More
Trastuzumab Deruxtecan Shows Efficacy Over T-DM1 in HER2+ Breast Cancer
September 18th 2021Patients with previously treated HER2-positive metastatic breast cancer experienced a clinically meaningful and statistically significant improvement in progression-free survival with fam-trastuzumab deruxtecan-nxki vs standard of care trastuzumab emtansine in the DESTINY-Breast03 trial.
Read More
In Cervical Cancer, The New Frontline SOC May Be Pembrolizumab/Chemo With or Without Bevacizumab
September 18th 2021In patients with persistent, recurrent, or metastatic cervical cancer the addition of pembrolizumab to chemotherapy with or without bevacizumab significantly improved survival and response rates.
Read More
TFI and PFS2 in Frontline Advanced Melanoma Improved With Relatlimab/Nivolumab
September 18th 2021In previously untreated patients with metastatic or unresectable melanoma, the addition of relatlimab to nivolumab prolonged benefit beyond initial treatment and first progression and reduced the risk of progression or death after the next line of systemic therapy vs nivolumab alone.
Read More
Osimertinib Plus Bevacizumab Does Not Improve PFS in EGFR-Mutated NSCLC
September 18th 2021Osimertinib (Tagrisso) plus bevacizumab does not produce a superior progression-free survival (PFS) benefit over osimertinib monotherapy in patients with non-squamous non-small cell lung cancer harboring an EGFR mutation. However, for patients who have a history of smoking or an exon 20 deletion, the combination may prove beneficial.
Read More
CheckMate 9ER Regimen Shows Efficacy Regardless of Prior Nephrectomy in RCC
September 18th 2021An exploratory subgroup analysis of the CheckMate 9ER trial discussed at the 2021 ESMO Congress showed significant benefits to progression-free survival for patients with renal cell carcinoma on nivolumab and cabozantinib regardless if they had prior nephrectomy.
Read More
Survival Benefit in Frontline Esophageal Squamous Cell Carcinoma Seen With Toripalimab/Chemo Combo
September 17th 2021In patients with advanced or metastatic esophageal squamous cell carcinoma regardless of PD-L1 expression, the addition of toripalimab to platinum-based chemotherapy demonstrated significantly improved survival outcomes.
Read More
pCR, EFS, Improved with Neoadjuvant Carboplatin Plus Paclitaxel, Without Veliparib in TNBC
September 17th 2021Pathological complete response rates and event-free survival in patients with treatment-naïve triple-negative breast cancer were improved with The addition of carboplatin to neoadjuvant paclitaxel followed by doxorubicin and cyclophosphamide.
Read More
Compared indirectly with real-world data of patients treated with standard of care, mobocertinib, a novel EGFR tyrosine kinase inhibitor, exhibited clinically meaningful activity in patients with non–small cell lung cancer who harbor EGFR exon 20 insertion mutations following frontline platinum-based chemotherapy.
Read More
Mobocertinib Global Maximum-Tolerated Dose is Found Tolerable in Japanese Patients With NSCLC
September 16th 2021Mobocertinib displayed a manageable safety profile across 40-mg, 120-mg, and 160-mg dose cohorts, leading to the determination of 160 mg as the maximum tolerated dose and recommended phase 2 dose for further study in Japanese patients with non–small cell lung cancer.
Read More
Limited Clinical Activity in Second-Line Gastric/GEJ Cancer Seen With Linagliptin/Atezolizumab Combo
September 16th 2021Limited responses as a second-line treatment for patients with locally advanced or metastatic gastric or gastroesophageal junction cancer were seen with Linagliptin plus atezolizumab.
Read More
High Responses to Dostarlimab in Endometrial Cancer Linked to TMB-H Status
September 16th 2021High responses to single-agent dostarlimab-gxly were seen in patients with endometrial cancer who had a high tumor mutational burden, irrespective of mismatch repair or microsatellite stability status.
Read More
Comparable Safety Profile Seen With The Addition of Darolutamide to ADT Among Patients With nmCRPC
September 16th 2021Compared with a placebo, darolutamide demonstrated a similar safety profile in men with nonmetastatic castration-resistant prostate cancer (nmCRPC) continuing androgen-deprivation therapy, with comparable adverse event onset and occurrence rates.
Read More
Darolutamide Improves Episodic Memory Enzalutamide in Men With mCRPC Compared to Enzalutamide
September 16th 2021Darolutamide was statistically significantly associated with better episodic memory over enzaluamide, according to computerized cognitive assessment in men with metastatic castration-resistant prostate cancer.
Read More
DFS Benefit of Adjuvant Pembrolizumab Seen Across RCC Subgroups
September 14th 2021An impressive disease-free survival benefit was seen in patients with clear cell renal cell carcinoma with pembrolizumab as an adjuvant therapy following nephrectomy compared with placebo. This improvement was observed across subgroups.
Read More